--- title: A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis nct_id: NCT02424253 overall_status: COMPLETED phase: PHASE2 sponsor: Ziarco Pharma Ltd study_type: INTERVENTIONAL primary_condition: Atopic Dermatitis countries: Belgium, Germany, Poland, United Kingdom canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02424253.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02424253" ct_last_update_post_date: 2021-06-10 last_seen_at: "2026-05-12T06:25:36.785Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis **Official Title:** A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Effects of 8 Weeks Treatment With Oral ZPL-3893787 (30 mg od x 56 Days) on Pruritus in Adult Subjects With Moderate to Severe Atopic Dermatitis **NCT ID:** [NCT02424253](https://clinicaltrials.gov/study/NCT02424253) ## Key Facts - **Status:** COMPLETED - **Phase:** PHASE2 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 98 - **Lead Sponsor:** Ziarco Pharma Ltd - **Conditions:** Atopic Dermatitis - **Start Date:** 2015-05-18 - **Completion Date:** 2016-02-03 - **CT.gov Last Update:** 2021-06-10 ## Brief Summary This was a randomized, double blind, placebo controlled, parallel group study in approximately 90 subjects with moderate-severe AD Eczema Area and Severity Index (EASI) ≥12 and ≤ 48 (0-72 scale). Following a run-in subjects were randomized to receive either oral 30 mg ZPL-3893787 once daily (od) or placebo od for 8 weeks (56 days). ## Eligibility - **Minimum age:** 18 Years - **Maximum age:** 65 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: Males and females aged 18-65 years inclusive with physician documented history or diagnosis of atopic dermatitis for at least 12 months prior to screening. Chronic AD should be diagnosed by the Eichenfield revised criteria of Hanifin and Rajka (Eichenfield, 2004) Eczema Area and Severity Index (EASI) of ≥12 and \<48. An Investigator's Global Assessment (IGA) score ≥ 3 at both Screening and Day 0. A mean pruritus score of ≥ 5 on a 0-10 scale over the 7 day Run In (Days -7 to -1) Atopic dermatitis affecting ≥10% BSA Exclusion Criteria: AD of such severity (EASI \>48) that the subject could not comply with the demands of the study and/or the subject is not a suitable candidate for a placebo-controlled study Have concurrent skin disease (e.g. acne) of such severity in the study area that it could interfere with the study evaluation or presence of skin comorbidities that may interfere with study assessments. Have an active skin infection or any other clinically apparent infections. Hypersensitivity to mometasone or to any other ingredients contained by the topical corticosteroid product used as rescue medication in the study. Have received phototherapy (e.g. UVA, UVB), or systemic therapy (e.g. immunosuppressants, cytostatics) known or suspected to have an effect on AD, within 4 weeks of the start of the Run In. Have received systemic corticosteroids (\[CS\] e.g. oral, intravenous, intraarticular, rectal) within 4 weeks of the start of the Run in. Subjects on a stable maintenance dose (over the preceding 3 months) of inhaled or intranasal CS may participate. Were treated with oral antihistamines or topical calcineurin inhibitors or topical steroids within 7 days of starting Run In; intranasal antihistamines for the treatment of allergic rhinitis are acceptable. ``` ## Arms - **ZPL-3893787** (EXPERIMENTAL) — 30 mg ZPL-3893787 orally once daily for 8 weeks. - **Placebo** (PLACEBO_COMPARATOR) — 1 capsule orally once daily for 8 weeks. ## Interventions - **ZPL-3893787** (DRUG) — ZPL-3893787 - **Placebo** (DRUG) — Matched Placebo ## Primary Outcomes - **Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch)** _(time frame: Baseline to Week 8)_ — The participant used the Pruritus NRS to rate his or her worst itch in the previous 12 hours. This was assessed twice daily (in the morning soon after rising and the evening prior to retiring) and recorded in the eDiary. The scale ranges from 0 (no itching) to 10 (itching as bad as can be imagined). If only 1 measurement was collected on a particular day, that score was counted as the worst measurement. ## Secondary Outcomes - **Change From Baseline in Eczema Area and Severity Index (EASI) Score** _(time frame: Baseline to Week 8)_ ## Locations (17) - Belgium Study Site, Brussels, Belgium - Belgium Study Site, Leuven, Belgium - Belgium Study Site, Liège, Belgium - German Study Site, Goch, Germany - German Study Site, Hamburg, Germany - German Study Site, Hanover, Germany - German Study Site, Mainz, Germany - German Study Site, Münster, Germany - Polish Study Site, Bialystok, Poland - Polish Study Site, Gdansk, Poland - Polish Study Site, Lodz, Poland - Polish Study Site, Poznan, Poland - Polish Study Site, Tarnów, Poland - UK Study Centre, Blackpool, United Kingdom - UK Study Centre, Cannock, United Kingdom - UK Study Centre, Leeds, United Kingdom - UK Study Centre, Manchester, United Kingdom ## Recent Field Changes (last 30 days) - `locations.german study site|mainz||germany` — added _(2026-05-12)_ - `locations.german study site|münster||germany` — added _(2026-05-12)_ - `locations.polish study site|bialystok||poland` — added _(2026-05-12)_ - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `locations.polish study site|gdansk||poland` — added _(2026-05-12)_ - `locations.polish study site|lodz||poland` — added _(2026-05-12)_ - `locations.polish study site|poznan||poland` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.belgium study site|brussels||belgium` — added _(2026-05-12)_ - `locations.belgium study site|leuven||belgium` — added _(2026-05-12)_ - `locations.belgium study site|liège||belgium` — added _(2026-05-12)_ - `locations.german study site|goch||germany` — added _(2026-05-12)_ - `locations.german study site|hamburg||germany` — added _(2026-05-12)_ - `locations.german study site|hanover||germany` — added _(2026-05-12)_ - `locations.polish study site|tarnów||poland` — added _(2026-05-12)_ - `locations.uk study centre|blackpool||united kingdom` — added _(2026-05-12)_ - `locations.uk study centre|cannock||united kingdom` — added _(2026-05-12)_ - `locations.uk study centre|leeds||united kingdom` — added _(2026-05-12)_ - `locations.uk study centre|manchester||united kingdom` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT02424253.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT02424253* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*